Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Dermatology: Acne (Oct 2017)

Posted by Matt Breese on Oct 30, 2017

Find me on:

According to our recent payer coverage analysis for dermatology-acne, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: While market access under medicare formularies remained stable over the past two quarters, we see a further increase in restricted lives across commercial and health exchange formularies. Additionally, the percentage of multipl product step edits increased.

mmit-reality-check-derm 4Q.png

Source: MMIT data as of Q4 2017

Trends: Manufacturers face a complicated ecosystem due to the market access variances across each coverage channel. This complexity increases as new products enter the market and shift the way payers decide formulary coverage. New biologic market entrants, like Eucrisa and Dupixent, create a new layer of treatment after TCI and TCS.

To read the full Reality Check on Dermatology with key findings on clinical characteristics, acne drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing